CbsBioscience is committed to develop innovative diagnostic products and services that deliver high medical value to both physicians and patients.
We successfully commercialized the first clinically validated genomic test to predict the prognosis of liver cancer.
- 2019
- MoU signed with K-MASTER Group, WHMU(Japan) and I.R.C.C.S.(Italy)
- 2018
- Contracted with KCSG (Korean Cancer Study Group) for database construction and data analysis service
- 2017
- Notification of non-reimbursement test for OncoHepaTest®
- 2016
- Anti-cancer regimen clinical trial IRB approval (13 hospitals)
- Eurostars2 Grant
- 2015
- Appointed as human genome clinical translational research collaborator post-genome multi-ministry genome project R&'D Business (Ministry of Health and Welfare)
- 2014
- Phase 2b IND approval for anti-cancer regimen including CDx Test from KFDA
- Appointed to KFDA PHARM NAVI for product commercialization project
- 2013
- OncoHepaTest® Q-Kit, OncoHepa CDx-Kit, 3rd Class Approval from KFDA
- Liver cancer drug development
- 2011
- liver cancer prognostic test contracted with domestic institutes
- (Ajou University hospital, Hanyang university medical center, Samsung Medical Center, Keimyung university dongsan medical center, Asan medical center, Korea university Anam hospital, Korea university Guro hospital, Korea university Ansan hospital)
- Overseas institutes (Mayo Clinic, Johns Hopkins Hospital etc.) co-research and MOU preparation
- Capital increase with consideration (Korea Investment Partners Co., Ltd)
- 2010
- Liver cancer prognostic test acquired domestic patent
- MOU signed with Asan medical center in cancer biomarker development
- OncoHepaTest® certified as a new Health Technology for HCC (Oct. 2010)
- Ministry of Knowledge Economy appointed as main participant for “local industrial technology development project”
- Initiation of the OncoHePaTest® service (Nov. 2010)
- 2009
- Co-research with Ajou university hospital, Hanyang university hospital
- Certified as Genetic Test & Testing Center
- Liver cancer prognostic test patent application (domestic & worldwide)
- 2008
- Ministry of Knowledge Economy appointed as participant for “Growth engine business”
- Ministry of Knowledge Economy appointed as work package leader for “Strategic development”
- Ministry of Science and Technology appointed as participant for “Excellent Research Center Project”
- 2007
- HCC prognostic biomarker discovery & development research (SMC & POSTECH)
- Commercialization of pathology expert system (Samsung Medical Center, KIST)
- The Small and Medium Business Administration appointed main participant for “Leading technology innovation development business”
- 2006
- Changed Name to CbsBioscience
- Appointed as INNOBIZ company / Appointed as Military Service Alternative Enterprise
- Second round development of FT-ICR MS operation system
- 2005
- Certified as a venture company
- Ministry of Commerce Industry and Energy appointed participant for "local R&D cluster establishment project"
- First round development of FT-ICR MS operation system<
- PINGS system acquired Korean patent
- 2004
- Foundation of laboratory affiliated with company
- Ministry of Oceans and Fisheries appointed as participant for "Fisheries specific research and development project"
- 2003
- Foundation of CBS SOFT
- Ministry of Commerce Industry and Energy appointed as main participant for "Mid-term base technology development business"
